HEALTHSTAT NEWS
STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax's experimental drug obefazimod showed strong efficacy in a Phase 3 trial for ulcerative colitis, with over 50% of participants achieving clinical remission. However, the company's shares dropped after reporting cancer cases among treated patients, raising safety concerns.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Johnson & Johnson advances IBD therapy, despite trial miss
- Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
- Chinese drug reduces lung cancer death risk by 34% in trial
- A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
- An experimental lung-cancer drug could replace Keytruda one day. But investors aren’t wowed.
- Groundbreaking bowel cancer trial follow-up shows zero relapses